2025-03-24-ITIF-后续生物制药创新对健康结果和经济增长的价值（英）_24页_407kb

Follow-On Biopharmaceutical Innovation Analysis Summary

Sandra Barbosu | March 2025

Core Value

Follow-on biopharmaceutical innovations build upon earlier discoveries to improve safety, efficacy, patient adherence, and therapeutic applications. These incremental innovations address unmet patient needs and drive economic benefits.

Key Takeaways

• Follow-on innovations refine existing therapies, expanding indications and improving adherence.
• Health benefits include enhanced treatment outcomes, improved quality of life, and economic savings.
• Innovation criteria vary by perspective (patients, payers, society), requiring broader evaluation beyond novelty.
• Policies like the Best Pharmaceuticals for Children Act (BPCA) and Orphan Drug Act (ODA) support follow-on growth.

Follow-On Innovation Impact

Health Outcomes

• Patient-Centric Improvements: New formulations address side effects and simplify administration (e.g., transdermal patches, chewable tablets).
• Adherence and Compliance: Enhanced therapies reduce hospitalizations and work absenteeism.
• Expanded Applications: Includes new indications, pediatric use, and resource-limited setting formulations.

Economic Benefits

• Cost Reduction: Competition and repurposing lower prices while ensuring access.
• Productivity Gains: Better adherence reduces health-care utilization costs.
• R&D Efficiency: Follow-on R&D contributes significantly to overall industry productivity.

Productivity

Follow-on innovations drive up to 30% higher health impact per R&D dollar than radical innovations alone.

Types of Follow-On Innovation

1. New Uses/Indications: Drug repurposing for novel conditions (e.g., sildenafil from angina to ED).
2. New Patient Populations: Tailored formulations for elderly, children, and populations in low-resource settings.
3. New Formulations: Improved safety and efficacy (e.g., Genvoya formula).
4. New Dosage Forms: Extended-release pills, once-weekly dosing, transdermal patches.

Misconceptions Debunked

• Triviality: Post-approval R&D is essential for clinical progression and economic viability.
• Market Manipulation: Competition ensures value-based access, not artificial exclusivity.
• Generic Barriers: Generic drugs enter upon patent expiry; follow-on drugs compete directly.

Policy Implications

• Support needed for financing follow-on R&D, patent protection, and avoiding policy disincentives.
• Policies like BPCA and ODA successfully incentivize pediatric and rare disease research.
• Regulations like the Inflation Reduction Act (IRA) pose risks to innovation; targeted reforms are necessary.

Conclusion
Follow-on biopharma innovation is critical to health outcomes and economic growth, requiring supportive policies to sustain development and ensure equitable access.